By: Marcia Frellick
Women have been underrepresented as first and senior authors for phase 3 solid tumor trials presented at the ASCO Annual Meeting over the past decade, according to data presented at this year’s conference (Abstract 9006). Researchers suggest that the lower number of female senior authors is particularly notable.




